glp 1 agonist history Discovery of GLP-1–Based Drugs for the Treatment of Obesity The expanding landscape of GLP-1

Firstly, this study is the first drug-target MR study to comprehensively investigate the specific impact of GLP-1RAs on SA, and we explored the possible mechanism of GLP-1RA through mediation analysis

In July 2024 , Genentech , a member of the Roche Group announced positive topline results from two arms of an ongoing multi-part Phase I clinical trial for CT-996, an investigational, once-daily, oral small molecule GLP-1 receptor agonist being developed for the treatment of both type 2 diabetes and obesity

Published: Version of record: Issue date: DOI:

Circ Res 116(9):15091526

First: plan for long-term, possibly lifelong therapy

Therefore, if and how GLP-1 RAs should be discontinued before surgery is a matter of debate